Noninvasive visualization of coronary calcinosis in patients with chronic terminal hepatopathy

Dynamics of a coronary artery calcium index as a factor of a cardiovascular risk in chronic terminal hepatopathy patients who need transplantation is determined. A prospective single-center cohort study was done and included 250 patients who need liver transplantation. The observation time was 5.4 ± 3.29 years from the moment of putting a patient on the waiting list. In addition to the assessment of occurrence and dynamics of traditional cardiovascular risk factors, calcium index indicators were determined by the method of multispiral computer tomography at the stage of including a patient into the study and after fve years of dynamic monitoring. The calcium index indicator in chronic terminal hepatopathy patients who need transplantation exceeded the limits of the recommended norm defned by a value of the 75th percentile, in 56.3 % (n = 152) of the examined patients at the stage of putting them on the waiting list. While comparing the coronary calcinosis indicators after fve years of dynamic monitoring the recipients of the liver transplants showed higher values of the calcium index in comparison with the patients with chronic terminal hepatopathy who did not receive the donor organ (CI, AJ-130 – 223 (38; 597) and 141 (4; 176) units respectively, p < 0.05; CI, Volume-130 – 314 (73; 748) and 203 (8; 284) mm2, respectively, p < 0.01), and the patients with metabolic syndrome (CI, AJ-130 – 186 (78; 463) and 74 (21; 192) units respectively, p < 0.01; CI, Volume-130 – 278 (74; 623) and 124 (74; 273) mm2 respectively, p < 0.01) and/or ischemic heart disease (CI, AJ-130 – 274 (102; 683) and 109 (34; 246) units respectively, p < 0.01; CI, Volume-130 – 382 (98; 834) and 382 (98; 834) mm2 respectively, p < 0.01) from the overall population. The obtained results make it possible to suppose that in addition to the radical solution to the liver defciency problem, the performance of orthotopic liver transplantations on patients with chronic terminal diseases accelerates the development of coronary atherosclerosis in the long-term postoperative period.

1. Di Tomaso G., Díaz-Zuccarini V., Pichardo-Almarza C. A. Multiscale model of atherosclerotic plaque formation at its early stage. IEEE Transactions on Biomedical Engineering, 2011, vol. 58, no. 12, pp. 3460–3463. https://doi.org/10.1109/tbme.2011.2165066

2. Lara M. J., Ros E., Sierra M., Dorronsoro C., Aguilar J. Composition and Genesis of Calcium Deposits in Atheroma Plaques. Ultrastructural Pathology, 2014, vol. 38, no. 3, pp. 167–177. https://doi.org/10.3109/01913123.2013.829149

3. McCarty M. F., DiNicolantonio J. J. The Molecular Biology and Pathophysiology of Vascular Calcifcation. Postgraduate Medical Journal, 2014, vol. 126, no. 2, pp. 54–64. https://doi.org/10.3810/pgm.2014.03.2740

4. Marcu L., Jo J. A., Fang Q., Papaioannou T., Reil T., Qiao J. H., Baker J. D., Freischlag J. A., Fishbein M. C. Detection of rupture-prone atherosclerotic plaques by time-resolved laser-induced fluorescence spectroscopy. Atherosclerosis, 2009, vol. 204, no. 1, pp. 156–164. https://doi.org/10.1016/j.atherosclerosis.2008.08.035

5. Mauriello A., Sangiorgi G., Fratoni S., Palmieri G., Bonanno E., Anemona L., Schwartz R. S., Spagnoli L. G. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. Journal of the American College of Cardiology, 2005, vol. 45, no. 10, pp. 1585–1593. https://doi.org/10.1016/j.jacc.2005.01.054

6. Sadat U., Li Z.-Y., Young V. E., Graves M. J., Boyle J. R., Warburton E. A., Varty K., O’Brien E., Gillard J. H. Finite element analysis of vulnerable atherosclerotic plaques: a comparison of mechanical stresses within carotid plaques of acute and recently symptomatic patients with carotid artery disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, vol. 81, no. 3, pp. 286–289. https://doi.org/10.1136/jnnp.2009.190363

7. Toutouzas K., Benetos G., Karanasos A., Chatzizisis Y. S., Giannopoulos A. A., Tousoulis D. Vulnerable plaque imaging: updates on new pathobiological mechanisms. European Heart Journal, 2015, vol. 36, no. 45, pp. 3147–3154. https://doi.org/10.1093/eurheartj/ehv508

8. Amano H., Ikeda T., Toda M., Okubo R., Yabe T., Koike M., Saito D., Yamazaki J. Assessment of angiographic coronary calcifcation and plaque composition in virtual histology intravascular ultrasound. Journal of Interventional Cardiology, 2015, vol. 28, no. 2, pp. 205–214. https://doi.org/10.1111/joic.12189

9. Jang I.-K., Bouma B. E., Kang D.-H., Park S.-J., Park S.-W., Seung K.-B. [et al.]. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. Journal of the American College of Cardiology, 2002, vol. 39, no. 4, pp. 604–609. https://doi.org/10.1016/s0735-1097(01)01799-5

10. Agatston A. S., Janowitz W. R., Hildner F. J., Zusmer N. R., Viamonte M. Jr., Detrano R. Quantifcation of coronary artery calcium using ultrafast computed tomography. Journal of the American College of Cardiology, 1990, vol. 15, no. 4, pp. 827–832. https://doi.org/10.1016/0735-1097(90)90282-t

11. Budoff M. J., Achenbach S., Blumenthal R. S., Carr J. J., Goldin J. G., Greenland P. [et al.]. Assessment of coronary artery disease by cardiac computed tomography. Circulation, 2006, vol. 114, no. 16, pp. 1761–1791. https://doi.org/10.1161/circulationaha.106.178458

12. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journal of Hepatology, 2010, vol. 53, no. 3, pp. 397–417. https://doi.org/10.1016/j.jhep.2010.05.004

13. Bogomolov P. O., Bueverov A. O., Vetshev P. S., Volkova N. N., Eramishantsev A. K., Zolotarevskii V. B. [et al.] Hepatic diseases of the biliferous ducts. 2nd ed. Moscow, Izdatel’skii dom «M-Vesti» Publ., 2002. 546 p. (in Russian).

14. Raval Z., Harinstein M. E., Skaro A. I., Erdogan A., DeWolf A. M., Shah S. J. [et al.]. Cardiovascular risk assessment of the liver transplant candidate. Journal of the American College of Cardiology, 2011, vol. 58, no. 3, pp. 223–231. https://doi.org/10.1016/j.jacc.2011.03.026

15. Møller S., Henriksen J. H. Cirrhotic cardiomyopathy. Journal of Hepatology, 2010, vol. 53, no. 1, pp. 179–190. https:// doi.org/10.1016/j.jhep.2010.02.023. Epub. 2010 Mar 31.

16. Alqahtani S. A., Fouad T. R., Lee S. S. Cirrhotic cardiomyopathy. Seminars in Liver Disease, 2012, vol. 28, no. 1, pp. 059–069. https://doi.org/10.1055/s-2008-1040321

17. Aydinalp A., Bal U., Atar I., Ertan C., Aktas A., Yildirir A., Ozin B., Mudderisoglu H., Haberal M. Value of stress myocardial perfusion scanning in diagnosis of severe coronary artery disease in liver transplantation candidates. Transplantation Proceedings, 2014, vol. 41, no. 9, pp. 3757–3760. https://doi.org/10.1016/j.transproceed.2009.06.219

18. Yilmaz Y., Kurt R., Yonal O., Polat N., Celikel C. A., Gurdal A. [et al.]. Coronary flow reserve is impaired in patients with nonalcoholic fatty liver disease: association with liver f brosis. Atherosclerosis, 2010, vol. 211, no. 1, pp. 182–186. https://doi.org/10.1016/j.atherosclerosis.2010.01.049. Epub. 2010 Feb. 7.

19. Ocel J. J., Edwards W. D., Tazelaar H. D., Petrovic L. M., Edwards B. S., Kamath P. S. Heart and liver disease in 32 patients undergoing biopsy of both organs, with implications for heart or liver transplantation. Mayo Clinic Proceedings, 2004, vol. 79, no. 4, pp. 492–501. https://doi.org/10.4065/79.4.492

20. Torregrosa M., Aguade S., Dos L., Segura R., Gónzalez A., Evangelista A. [et al.]. Cardiac alterations in cirrhosis: reversibility after liver transplantation. Journal of Hepatology, 2005, vol. 42, no. 1, pp. 68–74. https://doi.org/10.1016/j.jhep.2004.09.008

21. Zambruni A., Trevisani F., Gülberg V., Caraceni P., Domenicali M., Cantarini M. C. [et al.]. Daily profle of circulating C-type natriuretic peptide in pre-ascitic cirrhosis and in normal subjects: relationship with renal function. Scandinavian Journal of Gastroenterology, 2007, vol. 42, no. 5, pp. 642–647. https://doi.org/10.1080/00365520601013739

22. Møller S., Henriksen J. H. Cardiovascular complications of cirrhosis. Gut, 2008, vol. 57, no. 2, pp. 268–278. https://doi.org/10.1136/gut.2006.112177

23. Pacher P., Bátkai S., Kunos G. Cirrhotic cardiomyopathy: an endocannabinoid connection? British Journal of Pharmacology, 2005, vol. 146, no. 3, pp. 313–314. https://doi.org/10.1038/sj.bjp.0706332

24. Naschitz J. E., Slobodin G., Lewis R. J., Zuckerman E., Yeshurun D. Heart diseases affecting the liver and liver diseases affecting the heart. American Heart Journal, 2000, vol. 140, no. 1, pp. 111–120. https://doi.org/10.1067/mhj.2000.107177

25. Mit’kovskaya N. P., Rummo O. O., Grigorenko E. A. Stratifcation of Sudden death risk in liver and kidney transplant recipients on the active waiting list. Kardiologiya v Belarusi = Cardiology in Belarus, 2014, no. 3, pp. 27–33 (in Russian)